Welcome to our dedicated page for Armata Pharmctcl news (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmctcl stock.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) generates frequent news as a clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. News coverage of Armata often centers on its lead intravenous phage cocktail AP-SA02 for complicated Staphylococcus aureus bacteremia and its multi-phage candidate AP-PA02 targeting Pseudomonas aeruginosa in chronic respiratory disease.
Readers following ARMP news can expect detailed updates on clinical trial milestones, including topline data, late-breaking conference presentations, and regulatory interactions. Recent announcements have described positive Phase 1b/2a results from the diSArm study of AP-SA02, higher and earlier cure rates compared with antibiotics alone, and an End-of-Phase 2 written response from the U.S. Food and Drug Administration supporting advancement of AP-SA02 into a planned Phase 3 superiority study in complicated S. aureus bacteremia.
Armata’s news flow also includes information on manufacturing and infrastructure, such as the formal commissioning of its cGMP phage manufacturing facility in Los Angeles, California, which is intended to support late-stage clinical development and potential commercial production. Financial and corporate updates appear in quarterly results releases, describing grant and award revenue from the U.S. Department of Defense, secured credit agreements with Innoviva Strategic Opportunities LLC, and at-the-market equity offering arrangements.
Additional coverage highlights scientific publications and conference participation, including structural biology work on phage Pa223 in the Journal of Molecular Biology and presentations at IDWeek, the Military Health System Research Symposium, and the Evergreen Phage Meeting. For investors, clinicians, and researchers, this news page offers a centralized view of Armata’s progress in phage therapy, regulatory dialogue, funding developments, and manufacturing readiness. Bookmark this page to review ongoing ARMP press releases, SEC-linked disclosures, and other company communications as they are released.
Armata Pharmaceuticals (NYSE American: ARMP) announced FDA clearance for its Investigational New Drug application to initiate a Phase 2 clinical trial of AP-PA02 for non-cystic fibrosis bronchiectasis (NCFB). This condition, often linked to lung infections, currently has no approved treatments. The trial aims to assess the efficacy of AP-PA02 against Pseudomonas aeruginosa infections. Additionally, Armata is advancing other candidates for various bacterial infections, supported by recent financing.
Armata Pharmaceuticals (NYSE American: ARMP) announced its participation in two investor conferences in February and March 2022. The first event is BioCom California's 12th Annual Global Life Science Partnering Conference, taking place from February 22-24, where Pierre Kyme will present on February 23 at 3:30 PM PT. The second event is the 2nd Annual Chardan Microbiome Medicines Summit on March 1, featuring Brian Varnum at 10:00 AM ET. Armata specializes in bacteriophage therapeutics targeting antibiotic-resistant infections.
Innoviva reported substantial financial results for Q4 and full year 2021, with royalties rising by 18% to $111.1 million for Q4 and 19% to $405.7 million for the full year. Income from operations increased by 23% to $104.5 million in Q4 and 17% to $375.1 million for the year. Despite a $42.9 million decline in fair values of investments due to market volatility, the overall position remained strong with $201.5 million in cash and equivalents. A strategic investment of $45.0 million in Armata Pharmaceuticals is also highlighted.
Armata Pharmaceuticals announced a securities purchase agreement to sell common stock and warrants to Innoviva, raising $45 million before expenses. The funding will support Armata's clinical pipeline, particularly for AP-PA02 and AP-SA02, which target chronic Pseudomonas aeruginosa infections and complicated Staphylococcus aureus bacteremia, respectively. Innoviva will purchase 9 million shares at $5.00 each, with transactions occurring in two tranches. The second tranche is contingent on shareholder approval and is expected by the end of Q1 2022.
Armata Pharmaceuticals (NYSE American: ARMP) announced enhancements to its lead bacteriophage product candidate, AP-PA02, increasing its potency and coverage against Pseudomonas aeruginosa strains in cystic fibrosis and non-cystic fibrosis bronchiectasis patients. The new formulation introduces two additional phage genera, achieving over 90% coverage of tested isolates. Armata plans to enter a Phase 2 trial for non-cystic fibrosis bronchiectasis in 2022. The company is also developing a distinct phage cocktail for pneumonia. These advancements align with Armata's strategy to improve bacteriophage therapy effectiveness.
Armata Pharmaceuticals (NYSE American: ARMP) announced significant progress in its phage therapeutic development programs. The FDA has cleared its IND for the Phase 1b/2a trial of AP-SA02 targeting Staphylococcus aureus bacteremia, expected to start by year-end. Additionally, a $2 million milestone under the CF Foundation's Therapeutics Development Award has been achieved, raising the total to $3.75 million. The company is focused on combating drug-resistant bacterial infections with support from the Cystic Fibrosis Foundation and U.S. Department of Defense.
Armata Pharmaceuticals (ARMP) reported its third quarter 2021 results, revealing a loss from operations of $(6.1) million compared to $(5.6) million in Q3 2020. The company appointed Brian Varnum as CEO, succeeding Todd C. Patrick. Key developments included a $3.0 million equity investment from the Cystic Fibrosis Foundation and a $15 million award from the U.S. Department of Defense to support the AP-SA02 program. Research and development expenses rose to $5.6 million, indicating increased clinical trial activity. Armata's cash reserves grew to $12.1 million as of September 30, 2021.
Armata Pharmaceuticals announced that its Vice President of Clinical Development, Mina Pastagia, will present at the 2021 World Antimicrobial Resistance Congress in Washington D.C. on November 8. The presentation, titled A genomics-based approach for developing phage therapeutics targeting respiratory infections, will take place during the Innovation Showcase session at 2:30 pm ET.
This congress, now in its seventh year, will draw over 400 attendees and feature more than 150 speakers, focusing on antimicrobial resistance.
Armata Pharmaceuticals (NYSE American: ARMP) has announced a new lease for a 56,300 square-foot research and development and GMP manufacturing facility in Los Angeles. This state-of-the-art facility aims to enhance Armata's phage therapy pipeline and manufacturing capacity, supporting upcoming pivotal studies and commercial launches. The company is advancing its clinical candidates, AP-PA02 and AP-SA02, and believes the facility will facilitate potential strategic partnerships to bolster its pipeline and accelerate development.
Armata Pharmaceuticals (NYSE American: ARMP) announced receiving a $3.0 million equity investment from the Cystic Fibrosis Foundation, with an additional $4.0 million from Innoviva, a significant shareholder. This investment will support Armata's lead clinical candidate, AP-PA02, currently in a Phase 1b/2a trial for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients. This follows a prior $5.0 million Therapeutics Development Award from the Foundation in March 2020, emphasizing the urgent need for new therapies against difficult bacterial infections.